Non Hodgkin Lymphoma Clinical Trial
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.
PURPOSE: This clinical trial is studying how well four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant work in treating patients with relapsed or refractory hematologic cancer.
To determine the survival at day 100 of patients with relapsed, refractory, or poor-risk hematological malignancies treated with four different preparative regimens followed by allogeneic hematopoietic stem cell transplantation (HSCT) using two unrelated umbilical cord blood (UCB) units.
To determine the incidence and timing of neutrophil engraftment in patients treated with these regimens.
To determine the incidence and timing of platelet engraftment in patients treated with these regimens.
To determine the incidence and severity of acute and chronic graft-versus-host-disease (GVHD) in patients treated with these regimens.
To determine the survival at day 180 in patients treated with these regimens.
To determine the disease-free survival in patients treated with these regimens.
To determine the incidence of primary and secondary engraftment failure in patients treated with these regimens.
To determine the incidence of transplantation-related complications (e.g., infection, veno-occlusive disease of the liver, or organ toxicity) in these patients.
To determine the incidence of post-transplantation-related lymphoproliferative disease, secondary myelodysplastic syndromes, or other secondary malignancies in these patients.
To determine the incidence of relapse in patients treated with these regimens.
To determine post-transplantation chimerism in patients treated with these regimens.
To determine immune reconstitution in patients treated with these regimens.
OUTLINE: This is a multicenter study.
Preparative regimens: Patients are assigned to 1 of 4 preparative regimens.
Regimen 1 (for patients < 50 years of age and no contraindication to fractionated total-body irradiation (FTBI): Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2.
Regimen 2 (for patients < 50 years of age and unable to tolerate FTBI due to prior dose-limiting radiotherapy or significant cardiotoxicity): Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2.
Regimen 3* (for patients unable to tolerate regimen 1 or 2; no age exclusion): Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2.
Regimen 4* (for patients unable to tolerate regimen 1 or 2): Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2.
NOTE: *Treating physician decides the choice between regimen 3 and 4
Umbilical cord blood (UCB) transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover.
Graft-versus-host-disease prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
After completion of study therapy, patients are followed periodically.
Histologically confirmed hematological or lymphatic malignancy, including any of the following:
Acute myeloid leukemia
Relapsed or primary refractory disease with < 10% blasts on peripheral blood smear
In first remission with poor risk factors and molecular prognosis [i.e., AML with -5, -7, t(6;9), tri8, -11] (preparative regimen 3 or 4)
Acute lymphocytic leukemia
In second complete remission or higher OR in first remission with poor risk factors, including any of the following (preparative regimen 1 or 2):
BCR/ABL by fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction
t(9;22)(q34;q11) detected by cytogenetics
Chromosomes < 44 by cytogenetics
DNA index < 0.81 by flow cytometry
Any rearrangement of chromosome 11 that results in disruption of MLL gene (11q23) by cytogenetics and SER
In first remission with poor risk factors and molecular prognosis [ALL with Philadelphia chromosome-positive t(9;22), t(4;22), (q34;q11)] (preparative regimen 3 or 4)
Chronic myelogenous leukemia
In accelerated phase or greater (preparative regimen 1 or 2)
In accelerated or second chronic phase (preparative regimen 3 or 4)
With deletion of chromosome 7 or short arm of chromosome 5 (preparative regimen 1 or 2)
In high and high-intermediate risk categories (preparative regimen 3 or 4)
Non-Hodgkin lymphoma in relapse with marrow involvement
Refractory chronic lymphocytic leukemia
Patients deemed ineligible for conventional high-dose chemotherapy programs (i.e., regimens 1 or 2) due to any of the following concurrent medical conditions may be eligible for regimens 3 or 4 at the discretion of the treating physician and principal investigator (preparative regimen 3 or 4):
LVEF < 50% and > 40%
FEV1, FVC, or DLCO < 50%
Bilirubin > 3 mg/dL
Creatinine > 2 mg/dL
Two partially HLA-matched umbilical cord blood (UCB) units available
HLA-matched minimally at 4 of 6 HLA-A, HLA-B, and -DRB1 loci with the patient
DRB1 matched by high resolution DNA typing
HLA-A and HLA-B matched by low resolution at the "serological match" level
Two pooled units with a nucleated cell number > 2.5 x 10^7/kg
No available HLA-identical sibling or 1 antigen-mismatched related donor
No available HLA-matched unrelated bone marrow donor
See Disease Characteristics
Karnofsky performance status (PS) 60-100% OR Lansky PS 60-100% OR Zubrod PS 0-1
Physiological age 60 or less (at any chronological age)
Weight > 50 kg
Creatinine normal for age OR creatinine clearance by 24-hour urine collection or glomerular filtration rate > 60 mL/min
Bilirubin ≤ 1.5 mg/dL
LVEF ≥ 50%
DLCO ≥ 60% of predicted
No HIV-1 infection
No active uncontrolled infection
Negative pregnancy test
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Recovered from prior intensive chemotherapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Phoenix Arizona, 85006, United States
Duarte California, 91010, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.